Diabetes and Blood Pressure Medicines — With Targeted Therapy

Metformin does not act through the CYP3A4 enzyme, so it does not interact via the mechanism that causes most targeted therapy drug-level problems. It is generally considered compatible, and many people continue it throughout treatment. That said, tell your oncologist you are taking it — some targeted therapies can themselves affect blood glucose, and knowing you are on metformin helps your team interpret any change in your readings.

Amlodipine is generally considered lower risk than diltiazem or verapamil for CYP3A4 interactions. Whether it is continued, adjusted, or switched depends on which targeted therapy you are on. Tell your team at your next appointment and ask them to confirm whether your specific combination needs any change. Do not stop it without checking first — uncontrolled blood pressure carries its own risks during treatment.

Diltiazem and verapamil are the blood pressure medicines most often flagged in oncology drug-interaction reviews. Both significantly slow the CYP3A4 enzyme, which can raise your targeted therapy level well above the intended range. NCCN and ESMO guidance lists them as medicines to actively review when starting or continuing targeted therapy. If you are on either, raise it with your oncologist at your next appointment — or call the team before that if your treatment is starting soon.

It can be. Several targeted therapies are associated with changes in blood glucose — some raise it, others can lower it. If your readings have shifted since starting treatment, tell your oncologist rather than adjusting your diabetes medicine on your own. The change may need to be managed by your oncology team, your endocrinologist, or both together. Do not increase or reduce your diabetes medicine without that conversation, as the interaction between both treatments needs to be considered.

If the combination is not reviewed, your targeted therapy may run at a level higher or lower than intended — without anyone realising. Higher levels increase the risk of serious side effects. Lower levels may reduce how well the treatment is working. Neither is easy to detect without knowing the interaction exists. This is why the full medicine list matters at the very first appointment, not only when a problem appears.

For CYP3A4 interactions, timing the medicines separately does not solve the problem. A medicine like diltiazem or verapamil changes how the enzyme works throughout the day — it is not a moment-in-time effect. Separating doses by a few hours does not restore normal enzyme activity. If an interaction is identified, the usual solution is to switch to an alternative medicine that does not affect the enzyme, not to adjust timing. Ask your team before trying to manage it this way.

Yes, check before you start the new medicine if you can. Your GP may not have your targeted therapy prescription visible in their system, or may not know which enzyme it uses. Call your oncology team and let them know which medicine has been newly prescribed. In most cases they can review it quickly and confirm whether it is safe to take, or suggest an alternative your GP can prescribe instead. This is not an emergency — but it is worth a call before your first dose.

It can, in both directions. If a medicine significantly lowers your targeted therapy level by speeding up CYP3A4, less drug may be reaching the tumour than the treatment plan assumed. Over time, this can reduce the response. If another medicine raises the level by slowing CYP3A4, the side effect burden increases without added benefit — the treatment was designed for a specific range, not a higher one. Both scenarios are reasons to get the combination reviewed, and both are usually correctable once identified.